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S. Orsola-Malpighi University Hospital, Bologna, ItalyAbstractThe increasing prevalence of colistin resistance (ColR) Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (Kp) is a matter
of concern because of its unfavourable impact on mortality of KPC-Kp bloodstream infections (BSI) and the shortage of alternative
therapeutic options. A matched case–control–control analysis was conducted. The primary study end point was to assess risk factors for
ColR KPC-Kp BSI. The secondary end point was to describe mortality and clinical characteristics of these infections. To assess risk
factors for ColR, 142 patients with ColR KPC-Kp BSI were compared to two controls groups: 284 controls without infections caused by
KPC-Kp (control group A) and 284 controls with colistin-susceptible (ColS) KPC-Kp BSI (control group B). In the ﬁrst multivariate
analysis (cases vs. group A), previous colistin therapy, previous KPC-Kp colonization, 3 previous hospitalizations, Charlson score 3
and neutropenia were found to be associated with the development of ColR KPC-Kp BSI. In the second multivariate analysis (cases vs.
group B), only previous colistin therapy, previous KPC-Kp colonization and Charlson score 3 were associated with ColR. Overall, ColR
among KPC-Kp blood isolates increased more than threefold during the 4.5-year study period, and 30-day mortality of ColR KPC-Kp BSI
was as high as 51%. Strict rules for the use of colistin are mandatory to staunch the dissemination of ColR in KPC-Kp-endemic hospitals.
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p://dx.doi.org/10.1016/j.cmi.2015.08.001IntroductionBloodstream infections (BSI) due to Klebsiella pneumoniae
carbapenemase (KPC)-producing K. pneumoniae (KPC-Kp)
have become an important problem in many parts of theious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Giacobbe et al. Colistin-resistant KPC-producing Klebsiella pneumoniae BSIs 1106.e2world, including Italy, and are associated with high mortality
(40–60%) [1–9].
A favourable effect in terms of reduced mortality has been
observed in patients treated with colistin-based combination
therapy [1–4]. However, colistin resistance (ColR) among
KPC-Kp has been increasingly reported, especially in southern
Europe, and an association between reduced susceptibility to
colistin and increased mortality has been suggested [10–15]. In
this worrisome scenario, ColR might thus further threaten
patient survival from infections due to carbapenem-resistant
Enterobacteriaceae [10–12,16,17].
The aim of this multicenter study was to assess risk factors
for BSI due to colistin-resistant (ColR) KPC-Kp, as well as to
describe mortality and clinical characteristics of these infections.Materials and MethodsSetting, study design and patients
From January 2010 to June 2014, a retrospective study was
conducted in six large, full-service teaching hospitals in Italy. A
case–control–control design was used to study risk factors for
ColR KPC-Kp BSI. All adult patients (18 years old) who
developed a monomicrobial ColR KPC-Kp BSI during the study
period were deﬁned as cases. A ColR KPC-Kp BSI was deﬁned
as the presence of at least one ColR KPC-Kp–positive blood
culture with concomitant signs and symptoms of infection. The
case was deﬁned as healthcare-associated or hospital-acquired
infection according to standard deﬁnitions [18,19]. Cases
were identiﬁed via databases maintained by the microbiology
laboratories of the six hospitals, together with chart review.
Each patient was included in the study only once, at the time of
the ﬁrst KPC-Kp isolation from blood.
To assess risk factors for ColR KPC-Kp BSI, cases were
compared to two control populations. The ﬁrst control group
(control group A) included patients without KPC-Kp infections,
deﬁned as patients without BSI or KPC-Kp-positive culture of
any type during their index hospitalization; the second control
group comprised patients with monomicrobial colistin-
susceptible (ColS) KPC-Kp BSI (control group B). Two con-
trols per case were included in both populations. Controls
were matched to cases by participating hospital, type of ward
(medical, surgical or intensive care), date of hospital admission
(±1 month) and time at risk (±7 days). In patients with KPC-Kp
BSI (cases and group B) time at risk was deﬁned as the number
of days elapsing from hospital admission to the date of the ﬁrst
blood culture positive for KPC-Kp, while in patients without
KPC-Kp infections (group A) time at risk was deﬁned as the
number of days elapsing from hospital admission to hospital
discharge or in-hospital death.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfeIn addition to demographic data, other factors analysed as
possible risk factors for ColR KPC-Kp BSI included comorbidities
(also collectively expressed on the basis of Charlson index) [20],
presence of indwelling devices, previous isolation of multidrug-
resistant bacteria, previous colonization with KPC-Kp (deﬁned
as a KPC-Kp isolation from nonsterile sites during previous hos-
pitalizations in the absence of signs and symptomsof infection) and
several aspects of the patient’s recent medical history (e.g. con-
tacts with the healthcare system, receipt of immunosuppressive
therapies, receipt of chemotherapy/radiotherapy, previous anti-
biotic therapy). Table 1 lists the variables evaluated as possible risk
factors for ColR KPC-Kp BSI. Other variables, evaluated in pa-
tients with KPC-Kp BSI only for descriptive purposes, were
presentation with septic shock, severity of illness at infection
onset as reﬂected by the Pitt bacteremia score [21], source of
infection, adequacy of empirical antimicrobial treatment (empir-
ical treatment was deﬁned as inadequate unless it included at least
one drug displaying in vitro activity against the KPC-Kp isolate), the
number and type of drugs included in the postantibiogram treat-
ment regimen (depending on the number of in vitro–active drugs
they included (1 or >1), treatment regimens were classiﬁed as
monotherapy or combination therapy), clinical response to
postantibiogram therapy (with treatment failure being deﬁned as
death, or persistence or worsening of signs of infection after 72
hours of postantibiogram therapy) and survival at 30 days after the
positive blood culture.
Microbiological procedures
Isolates were identiﬁed with the Vitek 2 system (bioMérieux,
Marcy l’Etoile, France) and/or bymatrix-assisted laser desorption
ionization-time-of-ﬂight (MALDI-TOF) mass spectrometry
(MALDI Biotyper, Bruker Daltonics, Leipzig, Germany, or Vitek-
MS, bioMérieux). The in vitro susceptibility of the isolates was
assessed with the Vitek 2 system (bioMérieux) or the Sensititre
broth microdilution method (Trek Diagnostic Systems, Cleve-
land, OH, USA). Results were interpreted in accordance with the
European Committee on Antimicrobial Susceptibility Testing
(EUCAST) clinical breakpoints (http://www.eucast.org/
ﬁleadmin/src/media/PDFs/EUCAST_ﬁles/Breakpoint_tables/v_
5.0_Breakpoint_Table_01.pdf). The breakpoints used for
deﬁning nonsusceptibility to colistin, ertapenem andmeropenem
were as follows: minimum inhibitory concentration (MIC) >2 μg/
mL, >0.5 μg/mL and >2 μg/mL, respectively. The presence of
carbapenemase genes of blaKPC, blaNDM, blaVIM and blaOXA-48
types was determined by PCR reaction and DNA sequencing
analysis using previously described protocols [22,23].
Statistical analysis
The study primary aim was to assess factors associated with
ColR KPC-BSI. To this aim, the aforementioned variables werectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1106.e1–1106.e8
TABLE 1. Univariate analysis of risk factors for BSI caused by colistin-resistant KPC-Kp (case group) compared to control patients
without infections caused by KPC-Kp (control group A) and control patients with BSI caused by colistin-susceptible KPC-Kp
(control group B)
Variable
Case group
(n [ 142)
Control group A
(n [ 284)
Case group vs. control
group A
Control group B
(n [ 284)
Case group vs. control
group B
OR (95% CI) p OR (95% CI) p
Age (years), median (IQR) 66 (54–74) 70 (54–78) — 0.06 67 (55–77) — 0.23
Male sex 89 (62.7) 164 (57.7) 1.23 (0.80–1.90) 0.33 180 (63.4) 0.97 (0.63–1.51) 0.89
Comorbidities
COPD 14 (9.9) 46 (16.2) 0.56 (0.28–1.10) 0.08 41 (14.4) 0.65 (0.31–1.27) 0.18
Biliary devices 1 (0.7) 5 (1.8) 0.39 (0.01–3.59) 0.38 7 (2.5) 0.28 (0.01–2.22) 0.21
Cardiovascular diseases 53 (37.3) 130 (45.8) 0.70 (0.46–1.09) 0.10 120 (42.2) 0.81 (0.52–1.25) 0.33
Cerebrovascular diseases and dementia 15 (10.6) 43 (15.1) 0.66 (0.33–1.27) 0.19 35 (12.3) 0.84 (0.41–1.65) 0.59
Solid organ cancer 26 (18.3) 65 (22.9) 0.75 (0.43–1.28) 0.28 50 (17.6) 1.05 (0.59–1.82) 0.86
Hematologic cancer 26 (18.3) 25 (8.8) 2.32 (1.23–4.38) 0.004 43 (15.1) 1.26 (0.70–2.21) 0.40
Diabetes mellitus 30 (21.1) 54 (19.0) 1.14 (0.66–1.93) 0.60 71 (25.0) 0.80 (0.48–1.33) 0.37
Splenectomy 2 (1.4) 3 (1.1) 1.34 (0.11–11.81) 0.75 4 (1.4) 1 (0.09–7.07) 1.00
Chronic renal failure 23 (16.2) 35 (12.3) 1.37 (0.74–2.51) 0.27 54 (19.0) 0.82 (0.46–1.44) 0.48
Liver disease 13 (9.1) 14 (4.9) 1.94 (0.81–4.59) 0.09 27 (9.5) 0.96 (0.44–2.00) 0.91
HIV infection 3 (2.1) 3 (1.1) 2.02 (0.27–15.26) 0.38 13 (4.6) 0.45 (0.08–1.68) 0.21
Solid organ transplantation 13 (9.1) 5 (1.8) 5.62 (1.82–20.49) <0.001 21 (7.4) 1.26 (0.56–2.74) 0.53
Charlson score 3 41 (28.9) 36 (12.7) 2.79 (1.63–4.77) <0.001 39 (13.7) 2.25 (1.50–4.31) <0.001
History
Previous hospitalization 94 (66.2) 97 (34.1) 3.77 (2.41–5.92) <0.001 . 1.24 (0.80–1.93) 0.32
1 79 (55.6) 98 (34.5) 2.38 (1.54–3.67) <0.001 121 (42.6) 1.69 (1.10–2.59) 0.01
2 48 (33.8) 36 (12.7) 3.52 (2.08–5.94) <0.001 60 (21.1) 1.91 (1.18–3.06) 0.005
3 30 (21.1) 15 (5.3) 4.80 (2.39–9.96) <0.001 36 (12.7) 1.84 (1.04–3.25) 0.02
4 15 (10.6) 11 (3.9) 2.93 (1.21–7.25) 0.006 26 (9.1) 1.17 (0.56–2.39) 0.64
5 12 (8.4) 10 (3.5) 2.53 (0.97–6.70) 0.03 19 (6.7) 1.29 (0.55–2.89) 0.51
Outpatient follow-up 32 (22.5) 70 (24.6) 0.89 (0.53–1.46) 0.63 49 (17.2) 1.39 (0.81–2.36) 0.19
Admission from another healthcare facility 3 (2.1) 4 (1.4) 1.51 (0.22–9.05) 0.59 19 (6.7) 0.30 (0.06–1.05) 0.04
Previous ICU admission 38 (26.8) 12 (4.2) 8.28 (4.02–18.01) <0.001 54 (19.0) 1.56 (0.94–2.57) 0.07
Intravenous home therapy 2 (1.4) 2 (0.7) 2.01 (0.14–28.00) 0.48 2 (0.7) 2.01 (0.14–28.00) 0.48
Previous urinary tract infection 19 (13.4) 20 (7.0) 2.04 (0.99–4.17) 0.03 42 (14.8) 0.89 (0.47–1.64) 0.69
Recent bacterial infections 67 (47.2) 47 (16.5) 4.50 (2.79–7.28) <0.001 93 (32.7) 1.83 (1.19–2.83) 0.004
Previous MRSA isolation 5 (3.5) 5 (1.8) 2.04 (0.46–8.99) 0.26 13 (4.6) 0.76 (0.21–2.33) 0.61
Previous ESBL-producer isolation 12 (8.4) 4 (1.4) 6.46 (1.90–27.88) <0.001 20 (7.0) 1.22 (0.52–2.71) 0.60
Previous VRE isolation 1 (0.7) 2 (0.7) 1.00 (0.02–19.36) 1.00 3 (1.1) 0.66 (0.01–8.36) 0.72
Previous KPC-Kp colonization 51 (35.9) 8 (2.8) 19.39 (8.62–48.57) <0.001 49 (17.2) 2.69 (1.64–4.37) <0.001
Neutropenia 16 (11.3) 12 (4.2) 2.88 (1.23–6.86) 0.006 37 (13.0) 0.85 (0.42–1.63) 0.60
CVC 97 (68.3) 94 (33.1) 4.36 (2.77–6.88) <0.001 175 (61.6) 1.34 (0.86–2.11) 0.17
Nasogastric tube 42 (29.6) 45 (15.8) 2.23 (1.34–3.71) <0.001 61 (21.5) 1.53 (0.94–2.48) 0.06
Surgical drainage 21 (14.8) 28 (9.9) 1.59 (0.82–3.03) 0.13 51 (18.0) 0.79 (0.43–1.41) 0.41
Urinary catheter 85 (59.9) 125 (44.0) 1.90 (1.23–2.92) 0.002 159 (56.0) 1.17 (0.76–1.80) 0.45
Endoscopy 14 (9.9) 40 (14.1) 0.67 (0.32–1.31) 0.22 30 (10.6) 0.93 (0.44–1.88) 0.82
Mechanical ventilation 48 (33.8) 101 (35.6) 0.92 (0.59–1.45) 0.72 98 (34.5) 0.97 (0.62–1.51) 0.88
Dialysis 21 (14.8) 5 (1.8) 9.68 (3.43–33.45) <0.001 41 (14.4) 1.03 (0.55–1.87) 0.92
Total parenteral nutrition 31 (21.8) 41 (14.4) 1.65 (0.95–2.86) 0.05 83 (29.2) 0.68 (0.41–1.11) 0.10
Immunosuppressive therapy 18 (12.7) 12 (4.2) 3.29 (1.44–7.71) 0.001 25 (8.8) 1.50 (0.74–2.99) 0.21
Corticosteroid therapy 22 (15.5) 42 (14.8) 1.06 (0.57–1.91) 0.85 46 (16.2) 0.95 (0.52–1.70) 0.85
Chemotherapy/radiotherapy 18 (12.7) 69 (24.3) 0.45 (0.24–0.81) 0.005 39 (13.7) 0.91 (0.47–1.71) 0.76
PEG 4 (2.8) 5 (1.8) 1.62 (0.31–7.63) 0.47 8 (2.8) 1.00 (0.22–3.81) 1.00
Bedridden 30 (21.1) 64 (22.5) 0.92 (0.54–1.54) 0.74 51 (18.0) 1.22 (0.71–2.08) 0.43
Previous surgery 63 (44.4) 72 (25.3) 2.35 (1.50–3.67) <0.001 120 (42.2) 1.09 (0.71–1.67) 0.68
Recent antibiotic therapy
In general 119 (83.8) 210 (73.9) 1.82 (1.06–3.21) 0.02 240 (84.5) 0.95 (0.53–1.73) 0.85
By classes
Aminoglycosides 15 (10.6) 13 (4.6) 2.46 (1.05–5.79) 0.02 30 (10.6) 1.00 (0.48–2.00) 1.00
β-Lactam-β-lactamase inhibitor 53 (37.3) 109 (38.4) 0.96 (0.62–1.48) 0.83 150 (52.8) 0.53 (0.34–0.82) 0.002
Fluoroquinolones 47 (33.1) 87 (30.6) 1.12 (0.71–1.76) 0.60 95 (33.4) 0.98 (0.62–1.54) 0.94
Oxyiminocephalosporins 19 (13.4) 70 (24.6) 0.47 (0.26–0.84) 0.007 38 (13.4) 1.00 (0.52–1.87) 1.00
Carbapenems 45 (31.7) 33 (11.6) 3.53 (2.06–6.05) <0.001 92 (32.4) 0.97 (0.61–1.52) 0.88
Glycopeptides 39 (27.5) 37 (13.0) 2.53 (1.47–4.32) <0.001 62 (21.8) 1.35 (0.83–2.21) 0.20
Colistin 40 (28.2) 6 (2.1) 18.17 (7.31–53.62) <0.001 15 (5.3) 7.03 (3.60–14.25) <0.001
Other 49 (34.5) 61 (21.5) 1.93 (1.20–3.08) 0.004 80 (28.2) 1.34 (0.85–2.11) 0.18
Data are expressed as n (%) unless stated otherwise.
BSI, bloodstream infection; CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; CVC, central venous catheter; ESBL, extended-spectrum β-lactamase; HIV,
human immunodeﬁciency virus; ICU, intensive care unit; KPC-Kp, KPC-producing Klebsiella pneumoniae; IQR, interquartile range; MRSA, methicillin-resistant Staphylococcus aureus;
OR, odds ratio; PEG, percutaneous endoscopic gastrostomy; VRE, vancomycin-resistant enterococci.
1106.e3 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIcompared by the Mann-Whitney U test, the Student’s t test,
the χ2 test or the Fisher’s exact test, as appropriate. These
tests were performed for both comparisons (cases vs. control
group A and cases vs. control group B), and they were all two
sided. Once a univariate statistic was generated, variables with
a p value of <0.20 were included in two backward stepwiseClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectlogistic regression models (cases vs. control group A and cases
vs. control group B). The discrimination ability of the models
was assessed by estimating the area under the receiver
operating characteristic (ROC) curve. Calibration of the
models was assessed using the Hosmer-Lemeshow test for
goodness of ﬁt. Finally, to describe the outcome throughoutious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1106.e1–1106.e8
CMI Giacobbe et al. Colistin-resistant KPC-producing Klebsiella pneumoniae BSIs 1106.e4the 30th day after the ﬁrst positive blood culture, survival
distribution functions of both ColR and ColS KPC-Kp BSI
were estimated using the Kaplan-Meier product-limit method,
then compared using nonparametric log-rank and Wilcoxon
tests. Outcomes and clinical features in control group A pa-
tients were not reported. All statistical analyses were per-
formed by Intercooled Stata 11 for Windows (StataCorp,
College Station, TX, USA).ResultsDuring the study period, 729 BSIs due to KPC-Kp were
observed, of which 142 (19.5%) and 587 (80.5%) were due to
ColR and ColS strains, respectively. As shown in Fig. 1, the rate
of ColR among all KPC-Kp BSI increased signiﬁcantly over time,
and this was true for all participating hospitals (χ2 for trend,
p < 0.001). In terms of in vitro resistance, all ColR isolates were
resistant to penicillins, cephalosporins, ertapenem, ciproﬂoxa-
cin, amikacin, cotrimoxazole and chloramphenicol. Meropenem
MICs were 16 mg/L for more than two-thirds of ColR KPC-
Kp strains (94/142, 66.2%). As many as 116/142 (81.7%) and
111/142 (78.2%) ColR isolates were still susceptible to genta-
micin and tigecycline, respectively. However, from 2010 to the
ﬁrst 6 months of 2014, KPC-Kp resistance to gentamicin and
tigecycline increased from 6.3% to 20% (p 0.01) and from 9.4%
to 25.3% (p 0.01), respectively.
To understand the factors associated with the development
of ColR KPC-Kp BSI, cases were compared both with 284
patients without KPC-Kp infections (group A) and with 284
patients with ColS KPC-Kp BSI (group B). Controls were
matched with cases as deﬁned above; however, with regard toFIG. 1. Increase in colistin resistance (ColR) among blood Klebsiella
pneumoniae carbapenemase-producing K. pneumoniae isolates during
the study period (χ2 for trend, p <0.001).
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infetime at risk, two controls (group B) had time at risk longer (i.e.
>7 days) and ﬁve controls (group B) shorter (i.e. <7 days) than
their case counterpart.
Univariate analysis
As shown in Table 1, in the univariate analysis comparing cases
versus group A controls without KPC-Kp infection, signiﬁcant
factors included the following: receipt of a solid organ trans-
plant, Charlson score, number of previous hospitalizations,
previous intensive care unit (ICU) admission, previous bacterial
infections (excluding KPC-Kp), previous KPC-Kp colonization,
neutropenia, presence of indwelling devices, dialysis, total
parenteral nutrition, immunosuppressive therapy, chemo- and
radiotherapy, previous surgery and previous antibiotic therapy
with aminoglycosides, cephalosporins, carbapenems, glycopep-
tides and colistin. When cases were compared to ColS KPC-Kp
BSI (control group B), only Charlson score, number of previous
hospitalizations, previous bacterial infections, previous KPC-Kp
colonization and use of colistin were found to be signiﬁcantly
different between the two groups. Transfer from another
healthcare facility, which was not signiﬁcant in the cases versus
control A analysis, had a signiﬁcant p value in the cases versus
control B analysis.
Multivariate analyses
As shown in Table 2, in the multivariate comparison of cases vs.
control group A (no KPC-Kp infection), factors that remained
in the ﬁnal model were previous colistin therapy (odds ratio
(OR), 24.51, p <0.001), previous KPC-Kp colonization (OR,
18.71, p <0.001), 3 previous hospitalizations (OR, 5.32, p
<0.001), Charlson score 3 (OR, 2.84, p 0.001) and neu-
tropenia (OR, 2.72, p 0.04). Table 2 also shows the multivariate
comparison of cases versus control group B (ColS KPC-Kp
BSI). In this analysis, previous colistin administration was
conﬁrmed as a predictor of ColR KPC-Kp BSI (OR, 6.88, p
<0.001), along with previous KPC-Kp colonization (2.40, p
0.001) and Charlson score 3 (OR, 2.97, p <0.001). Both
multivariate models displayed good predictive ability because
the ROC area under the curve was 0.80 for the ﬁrst model
(cases vs. control group A) and 0.75 for the second (cases vs.
control group B). The results of Hosmer-Lemshow chi-square
testing (χ2 = 22.8; p 0.24 for the ﬁrst model and χ2 = 1.15; p
0.88 for the second model) were indicative of good calibration.
Clinical features of ColR and ColS KPC-Kp BSI and
outcome
As shown in Table 3, ColR KPC-Kp BSI were more often
associated with the lower respiratory tract as the source of
infection and inadequate empirical antibiotic treatment than
ColS KPC-Kp BSI. In general, ColR received a lower percentagectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1106.e1–1106.e8
TABLE 2. Multivariate analysis of risk factors for BSI caused by
colistin-resistant KPC-Kpa
Control group and risk factors OR (95% CI) p
Control group A (patients without KPC-Kp infection)b
Previous colistin administration 24.51 (8.75–68.67) <0.001
Previous colonization with KPC-Kp 18.71 (8.05–43.51) <0.001
Previous 3 hospitalization 5.32 (2.48–11.38) <0.001
Charlson score 3 2.84 (1.52–5.29) 0.001
Neutropenia 2.72 (1.02–7.23) 0.04
Control group B (patients with BSI due to colistin-susceptible KPC-Kp)c
Previous colistin administration 6.88 (3.55–13.34) <0.001
Previous colonization with KPC-Kp 2.40 (1.46–3.97) 0.001
Charlson score 3 2.97 (1.74–5.06) <0.001
BSI, bloodstream infection; CI, conﬁdence interval; KPC-Kp, KPC-producing
Klebsiella pneumoniae; OR, odds ratio.
aOnly variables retained in the ﬁnal multivariate models are presented.
bVariables with p < 0.20 in the univariate analysis (i.e. age, chronic obstructive
pulmonary disease, cardiovascular diseases, cerebrovascular diseases and dementia,
hematologic cancer, liver disease, solid organ transplantation, Charlson score 3,
previous hospitalization, previous 1 hospitalization, previous 2 hospitalization,
previous 3 hospitalization, previous 4 hospitalization, previous 5 hospitaliza-
tion, previous intensive care unit admission, previous urinary tract infections,
previous extended-spectrum β-lactamases-producer isolation, recent bacterial
infections, previous colonization with KPC-Kp, neutropenia, presence of central
venous catheter, presence of nasogastric tube, surgical drainage, presence of
urinary catheter, dialysis, chemotherapy/radiotherapy, total parenteral nutrition,
previous surgery, recent antibiotic therapy, recent therapy with aminoglycosides,
recent therapy with oxyiminocephalosporins, recent therapy with carbapenems,
recent therapy with glycopeptides, previous colistin administration, recent therapy
with antibiotics other than aminoglycosides, β-lactam-β-lactamase inhibitor,
ﬂuoroquinolones, colistin, oxyiminocephalosporins and glycopeptides) were
considered for the multivariate model of cases vs. control group A.
cVariables with p < 0.20 in the univariate analysis (i.e. chronic obstructive pulmo-
nary disease, Charlson score 3, previous 1 hospitalization, previous 3 hospi-
talization, admission from another healthcare facility, previous intensive care unit
admission, recent bacterial infections, previous colonization with KPC-Kp, presence
of central venous catheter, presence of nasogastric tube, total parenteral nutrition,
recent therapy with β-lactam-β-lactamase inhibitor, previous colistin
administration, recent therapy with antibiotics other than aminoglycosides,
β-lactam-β-lactamase inhibitor, ﬂuoroquinolones, colistin, oxyiminocephalosporins
and glycopeptides) were considered for the multivariate model of cases vs. control
group B.
TABLE 3. Characteristics of 426 patients with BSI caused by
KPC-Kp according to colistin resistance (ColR) or colistin
susceptibility (ColS) of the isolates
Variable
ColR patients, case
group (n [ 142)
ColS patients, control
group B (n [ 284) p
Type of infection
HCA infection 13 (9.1) 27 (9.5) 0.96
Hospital-acquired
infection
129 (90.8) 257 (90.5) 0.91
Septic shock 29 (20.4) 53 (18.7) 0.66
Pitt bacteremia score
4
53 (37.3) 82 (28.8) 0.07
Source of infection
Urinary tract 25 (17.6) 69 (24.3) 0.12
Lower Respiratory
tract
29 (20.4) 34 (11.9) 0.02
Pancreas and biliary
tract
3 (2.1) 8 (2.8) 0.66
Central venous
catheter
36 (25.3) 62 (21.8) 0.41
Surgical wound 13 (9.1) 28 (9.9) 0.82
Other 5 (3.5) 11 (3.9) 0.86
Unknown 40 (28.2) 89 (31.3) 0.50
Inadequate empirical
antimicrobial
treatment
94 (66.2) 155 (54.6) 0.02
Postantibiogram therapy
Colistin-including
therapy
14 (9.8) 208 (73.2) <0.001
Tigecycline-including
therapy
79 (55.6) 145 (51.1) 0.37
Gentamicin-including
therapy
66 (46.5) 77 (27.1) <0.001
Monotherapy 47 (33.1) 53 (18.6) <0.001
Combination therapy 95 (66.9) 231 (81.3) <0.001
Two-drug
combinations
36 (25.3) 78 (27.5) 0.64
Three-drug
combinations
49 (34.5) 151 (53.2) <0.001
Four drug
combinations
10 (7.1) 2 (0.7) <0.001
Carbapenem-
excluding
combinations
28 (19.7) 72 (25.4) 0.19
Carbapenem-
including
combinations
67 (47.2) 159 (55.9) 0.08
Double-carbapenem
combinations
15 (10.6) 6 (2.1) <0.001
Rifampin addition to
combinations
11 (7.7) 2 (0.7) <0.001
Outcome parameters
Initial treatment
failure
38 (26.7) 42 (14.8) 0.003
Death 73 (51.4) 112 (39.4) 0.02
Time to discharge
(days), median (IQR)a
27 (18–40) 20 (14–37) 0.04
Data are expressed as n (%) unless stated otherwise.
BSI, bloodstream infections; HCA, healthcare associated; KPC-Kp, KPC-producing
Klebsiella pneumoniae; IQR, interquartile range.
aTime to discharge was deﬁned as time (days) from date of index blood culture to
discharge of patients and calculated on patients who survived only.
1106.e5 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIof combination therapies, and in particular a lower number of
three-drug combinations. Gentamicin, double carbapenem
combinations and rifampin were more frequently used in ColR
KPC-Kp. ColR KPC-Kp BSI appeared to be associated with a
higher percentage of initial treatment failure (assessed at 72
hours after beginning of therapy) and of mortality than ColS
KPC-Kp BSI. Indeed, the overall 30-day crude mortality was
51% (73/142) versus 39.4% (112/284) for ColR and ColS cases,
respectively (p 0.02). The difference in mortality was also
shown by the Kaplan-Meier survival estimates, although the two
curves start to divaricate only after the eighth day after the ﬁrst
positive blood culture (Fig. 2).DiscussionThe increasing prevalence of ColR among KPC-Kp is of great
concern because of its apparent unfavourable impact on mor-
tality in KPC-Kp BSI and the dramatic shortage of alternative
therapeutic options [10,11,14,24]. To our knowledge, this is the
largest sample of patients with BSI due to ColR KPC-Kp re-
ported to date. The case–control–control design we applied toClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectthis study allowed a reliable comparison between variables
associated with ColS and ColR KPC-Kp BSI. The two pivotal
observations stemming from this study are, ﬁrst, that among all
KPC-Kp BSI, ColR increased more than threefold during the
4.5-year study period, and that previous colistin administration
was the strongest factor differentiating ColR cases from both
control groups.
The association between colistin administration and ColR was
already observed in three previous single-center studies. Mat-
thaiou et al. [16] reported 41 patients colonized or infected with
colistin-resistant Gram-negative rods, of which 33 wereious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1106.e1–1106.e8
FIG. 2. Kaplan-Meier survival curves of patients with bloodstream infection due to Klebsiella pneumoniae carbapenemase-producing K. pneumoniae
according to colistin resistance or susceptibility of isolates.
CMI Giacobbe et al. Colistin-resistant KPC-producing Klebsiella pneumoniae BSIs 1106.e6K. pneumoniae. Although various conditions, including age and
length of stay in the ICU, were initially associated with resistance,
only previous colistin treatment remained in the ﬁnal multivar-
iate model. Similarly, Kontopidou et al. [17] found an association
between previous colistin therapy and subsequent colonization
with ColR KPC-Kp. Finally, previous colistin therapy was an in-
dependent predictor of ColR KPC-Kp isolation among 254 ICU
patients in another Greek study [25]. Therefore, although
probably slightly overestimated in the comparison between
cases and control group B [26], the role of previous colistin
therapy as an independent risk factor for ColR KPC-Kp BSI was
strongly conﬁrmed in both multivariate models of our study,
underscoring the absolute need of avoiding unnecessary colistin
use in clinical practice. This requires the application of strict rules
for the initiation and, perhaps more importantly, early discon-
tinuation of colistin in clinical practice in hospitals that are
endemic for KPC-Kp infections.
Previous colistin administration is not the only factor
involved in the development of ColR, since 72% of BSI causedClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeby ColR KPC-Kp developed in patients without a history of
colistin administration. Indeed, in both multivariate models
(cases vs. control group A and cases vs. control group B), the
occurrence of ColR KPC-Kp BSI was also associated with
previous colonization with KPC-Kp. Although we cannot
exclude the notion that the two variables are somewhat
interconnected (because some colonized patients might have
received colistin), there is the possibility that these patients
might have been primarily colonized with ColR strains. Cross-
transmission of both ColS and ColR strains, irrespectively of
any previous antibiotic administration, has been demonstrated
[25]. In line with this hypothesis, in our study, the rate of
previous hospitalizations (and consequently the risk of coloni-
zation) did not signiﬁcantly differ between ColS and ColR pa-
tients, but it was higher in ColR patients compared to controls
without KPC-Kp infections.
It is of note that ColR patients had increased Charlson
scores compared to both ColS (p <0.001) and patients without
KPC-Kp infections (p 0.001). The underlying diseases and theirctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1106.e1–1106.e8
1106.e7 Clinical Microbiology and Infection, Volume 21 Number 12, December 2015 CMIseverity are often a silent but disturbing presence in this setting
and always play a pivotal role in the development of bacterial
and fungal severe infections. The great improvements of mod-
ern medicine and surgery have led to increased patient survival
from many severe diseases; however, this requires intensive
therapies, immunosuppression and repeated hospitalizations,
thus increasing the risk of acquisition of resistant organisms and
the administration of repeated, more or less appropriated
antibiotic therapies.
Consistently with previous reports [10,11], in our study the
mortality rate appeared to be higher in ColR than ColS KPC-Kp
BSI (51% vs. 39%). This ﬁnding supports the independent role of
ColR as a predictor of mortality, which has been already
observed in our cohort [10]. In this regard, the development of
ColR further reduces the already poor therapeutic armamen-
tarium for these patients, because colistin, more than other
drugs (tigecycline and gentamicin), is the backbone of therapy
for KPC-Kp infections, and this might have adversely affected
survival in our cohort. However, further studies with appro-
priate methodology are needed to accurately explore risk fac-
tors for mortality of ColR KPC-Kp BSI and to adequately weigh
the role of antimicrobial therapy against this backdrop.
This study has other limitations. Among them, we should
mention the fact that other unmeasured factors such as pre-
vious colistin exact duration and type of treatment (mono-
therapy vs. combination therapy) might have signiﬁcantly
contributed to the emergence of ColR strains. We could not
control for the role of cross-transmission from colonized pa-
tients in adjacent beds, a factor that has been previously shown
to be associated with ColR KPC-Kp acquisition [25]. However,
cases and controls were matched for hospital, ward, month of
admission and time at risk. Therefore, the relevance of cross-
transmission during the study period is unlikely to have been
strongly underestimated [27]. Moreover, we indirectly evalu-
ated the impact of cross-transmission during previous hospi-
talizations through the case–control–control design of the
study, as previously explained.
In conclusion, the use of colistin other than for the treat-
ment of culture-proven or highly suspected ColS KPC-Kp
invasive infections should be avoided. Obviously, there is an
urgent need for new antibiotics for treating these desperately ill
patients, but in the meantime, there is an even more urgent
need to staunch the dissemination of these resistant organisms.
Reports like this one might be pivotal for understanding the
phenomenon of increased antibiotic resistance, but they also
testify to the failure of our not negligible efforts to highlight the
dissemination of antibiotic resistance, which is endangering the
incredible improvements of modern medicine and surgery. To
counteract this trend, active, centrally driven and funded pro-
grams are urgently needed.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectTransparency DeclarationPartially supported by grants from the Italian Ministry for
University and Scientiﬁc Research (Fondi Ateneo Linea D-1
2014-2015). All authors report no conﬂicts of interest relevant
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